Literature DB >> 23973922

Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2.

Hyung-Sik Kim1, Tae-Hoon Shin, Byung-Chul Lee, Kyung-Rok Yu, Yoojin Seo, Seunghee Lee, Min-Soo Seo, In-Sun Hong, Soon Won Choi, Kwang-Won Seo, Gabriel Núñez, Jong-Hwan Park, Kyung-Sun Kang.   

Abstract

BACKGROUND & AIMS: Decreased levels or function of nucleotide-binding oligomerization domain 2 (NOD2) are associated with Crohn's disease. NOD2 regulates intestinal inflammation, and also is expressed by human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs), to regulate their differentiation. We investigated whether NOD2 is required for the anti-inflammatory activities of MSCs in mice with colitis.
METHODS: Colitis was induced in mice by administration of dextran sulfate sodium or trinitrobenzene sulfonic acid. Mice then were given intraperitoneal injections of NOD2-activated hUCB-MSCs; colon tissues and mesenteric lymph nodes were collected for histologic analyses. A bromodeoxyuridine assay was used to determine the ability of hUCB-MSCs to inhibit proliferation of human mononuclear cells in culture.
RESULTS: Administration of hUCB-MSCs reduced the severity of colitis in mice. The anti-inflammatory effects of hUCB-MSCs were greatly increased by activation of NOD2 by its ligand, muramyl dipeptide (MDP). Administration of NOD2-activated hUCB-MSCs increased anti-inflammatory responses in colons of mice, such as production of interleukin (IL)-10 and infiltration by T regulatory cells, and reduced production of inflammatory cytokines. Proliferation of mononuclear cells was inhibited significantly by co-culture with hUCB-MSCs that had been stimulated with MDP. MDP induced prolonged production of prostaglandin (PG)E2 in hUCB-MSCs via the NOD2-RIP2 pathway, which suppressed proliferation of mononuclear cells derived from hUCB. PGE2 produced by hUCB-MSCs in response to MDP increased production of IL-10 and T regulatory cells. In mice, production of PGE2 by MSCs and subsequent production of IL-10 were required to reduce the severity of colitis.
CONCLUSIONS: Activation of NOD2 is required for the ability of hUCB-MSCs to reduce the severity of colitis in mice. NOD2 signaling increases the ability of these cells to suppress mononuclear cell proliferation by inducing production of PGE2.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5,6-carboxy fluorescein succinimidyl ester; CFSE; CM; COX-2; DSS; Foxp3; IBD; IDO-1; IFN; IL; Immune Regulation; LPS; MDP; MLN; MLR; MNC; MPO; Mouse Model; NF-κB; NO; NOD2; PBS; PG; RIP; Signal Transduction; T-helper cell; TLR; TNBS; TNF; Th; Toll-like receptor; Treg; UCM; culture media; cyclooxygenase-2; dextran sulfate sodium; forkhead box p3; hMNC; hUCB-MSCs; human mononuclear cell; human umbilical cord blood-derived mesenchymal stem cells; indoleamine-2,3-dioxygenase-1; interferon; interleukin; lipopolysaccharide; mesenteric lymph node; mixed lymphocyte reaction; mononuclear cell; muramyl dipeptide; myeloperoxidase; nitric oxide; nuclear factor-κB; nucleotide-binding oligomerization domain 2; phosphate-buffered saline; prostaglandin; receptor-interacting protein; regulatory T cell; siRNA; small interfering RNA; trinitrobenzene sulfonic acid; tumor necrosis factor; umbilical cord blood-derived mesenchymal stem cell conditioned medium

Mesh:

Substances:

Year:  2013        PMID: 23973922     DOI: 10.1053/j.gastro.2013.08.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  76 in total

Review 1.  Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications.

Authors:  Nayoun Kim; Seok-Goo Cho
Journal:  Int J Hematol       Date:  2015-12-11       Impact factor: 2.490

2.  GDF-15 secreted from human umbilical cord blood mesenchymal stem cells delivered through the cerebrospinal fluid promotes hippocampal neurogenesis and synaptic activity in an Alzheimer's disease model.

Authors:  Dong Hyun Kim; Dahm Lee; Eun Hyuk Chang; Ji Hyun Kim; Jung Won Hwang; Ju-Yeon Kim; Jae Won Kyung; Sung Hyun Kim; Jeong Su Oh; Sang Mi Shim; Duk Lyul Na; Wonil Oh; Jong Wook Chang
Journal:  Stem Cells Dev       Date:  2015-08-19       Impact factor: 3.272

Review 3.  Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease.

Authors:  Raghavan Chinnadurai; Spencer Ng; Vijayakumar Velu; Jacques Galipeau
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

4.  Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion.

Authors:  Maneesh Dave; Yujiro Hayashi; Gabriella B Gajdos; Thomas C Smyrk; Phyllis A Svingen; Sergiy M Kvasha; Andrea Lorincz; Haidong Dong; William A Faubion; Tamas Ordog
Journal:  Gastroenterology       Date:  2015-01-28       Impact factor: 22.682

5.  Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients.

Authors:  Georgi Vasilev; Mariana Ivanova; Ekaterina Ivanova-Todorova; Kalina Tumangelova-Yuzeir; Ekaterina Krasimirova; Rumen Stoilov; Dobroslav Kyurkchiev
Journal:  Rheumatol Int       Date:  2019-04-03       Impact factor: 2.631

Review 6.  Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.

Authors:  Bojana Simovic Markovic; Tatjana Kanjevac; C Randall Harrell; Marina Gazdic; Crissy Fellabaum; Nebojsa Arsenijevic; Vladislav Volarevic
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

Review 7.  Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.

Authors:  Matthew W Klinker; Cheng-Hong Wei
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

Review 8.  Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Maneesh Dave; Kathan Mehta; Jay Luther; Anushka Baruah; Allan B Dietz; William A Faubion
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

9.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

10.  Human dental follicle mesenchymal stem cells alleviate T cell response in inflamed tissue of Crohn's patients.

Authors:  Noushin Zibandeh; Deniz Genc; Yazgul Duran; Munhtsetseg Banzragch; Sakina Sokwala; Kamil Goker; Ozlen Atug; Tunç Akkoç
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.